Identification of molecular compounds critical to Alzheimer's-like plaque formation

Journal of Neuroscience Research

Volumn 85, Issue 9, 2007, Pages 2037-2044

  Gellermann, Gerald P ^a,c   Ullrich, Kathrin ^a,b   Unger, Christiane ^a,b   Fändrich, Marcus ^a   Sauter, Simon ^b   Diekmann, Stephan ^a  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Aggregation; Drug screen; Prion; Protein folding

Indexed keywords

AMYLOID; CYTOCHALASIN D; DEXTRAN SULFATE; GENISTEIN; HEPARIN; INOSITOL; NOCODAZOLE; PROBENECID;

ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; ENDOCYTOSIS; HUMAN; HUMAN CELL; PHAGOCYTOSIS; PLAQUE FORMING CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CELLS, CULTURED; CHONDROITIN; CYTOCHALASIN D; DEXTRAN SULFATE; GENISTEIN; HEPARIN; HUMANS; INOSITOL; MACROPHAGES; MICROSCOPY, ELECTRON; MONOCYTES; NOCODAZOLE; PROBENECID; SENILE PLAQUES;

EID: 34447325936     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21311     Document Type: Article

References (51)

1. Atluru D, Jackson TM, Atluru S. 1991. Genistein, a selective protein tyrosine kinase inhibitor, inhibits interleukin-2 and leukotriene B4 production from human mononuclear cells. Clin Immunol Immunopathol 59:379-387.
2. Auton M, Bolen DW. 2005. Predicting the energetics of osmolyte-induced protein folding/unfolding. Proc Natl Acad Sci U S A 102:15065-15068.
3. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. 2005. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847.
4. Cassimeris LU, Wadsworth P, Salmon ED. 1986. Dynamics of microtubule depolymerization in monocytes. J Cell Biol 102:2023-2032.
5. Castillo GM, Lukito W, Wight TN, Snow AD. 1999. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 72:1681-1687.
6. Caughey B, Lansbury PT. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267-298.
7. Chiti F, Dobson CM. 2006. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366.
8. Chung H, Brazil MI, Soe TT, Maxfield FR. 1999. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 274:32301-32308.
9. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. 2006. Opposing activities protect against age-onset proteotoxicity. Science 313:1604-1610.
10. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. 2006. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflamm 3:27.
11. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. 2004. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 18:1749-1751.
12. Fändrich M, Forge V, Buder K, Kittler M, Dobson CM, Diekmann S. 2003. Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments. Proc Natl Acad Sci U S A 100:15463-15468.
13. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11-20.
14. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. 2003. Regulated secretion of macrophage migration inhibitory factor is mediated by a nonclassical pathway involving an ABC transporter. FEBS Lett 551:78-86.
15. Gandy S, Heppner FL. 2005. Alzheimer's amyloid immunotherapy: quo vadis? Lancet Neurol 4:452-453.
16. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, Schroeckh V, Leisner C, Lütkepohl T, Shtrasburg S, Röcken C, Pras M, Linke RP, Diekmann S, Fändrich M. 2005. Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci U S A 102:6297-6302.
17. Gellermann GP, Ullrich K, Tannert A, Unger C, Habicht G, Sauter SR, Hortschansky P, Horn U, Mollmann U, Decker M, Lehmann J, Fandrich M. 2006. Alzheimer-like plaque formation by human macrophages is reduced by fibrillation inhibitors and lovastatin. J Mol Biol 360:251-257.
18. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R, Morissette C, Paquette J. 2001. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 8(Suppl 1):28-35.
19. Goedert M. 1996. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann N Y Acad Sci 777:121-131.
20. Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185.
21. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
22. Harper JD, Lansbury PT Jr. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the timedependent solubility of amyloid proteins. Annu Rev Biochem 66:385-407.
23. Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, Nordhoff E, Lurz R, Schugardt N, Rautenberg S, Herhaus C, Barnickel G, Bottcher H, Lehrach H, Wanker EE. 2002. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc Natl Acad Sci U S A 99:16400-16406.
24. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fändrich M. 2005. The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Prot Sci 7:1753-1759.
25. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. 2005. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflamm 2:23.
26. Kisilevsky R. 2000. Amyloidogenesis-unquestioned answers and unanswered questions. J Struct Biol 130:99-108.
27. Kluve-Beckerman B, Liepnieks JJ, Wang L, Benson MD. 1999. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 155:123-133.
28. Kluve-Beckerman B, Manaloor JJ, Liepnieks JJ. 2002. A pulse-chase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum 46:1905-1913.
29. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357.
30. Lorenzo A, Yankner BA. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 91:12243-12247.
31. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245-4249.
32. McLaurin J, Franklin T, Chakrabartty A, Fraser PE. 1998. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J Mol Biol 278:183-194.
33. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. 2000. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem 275:18495-18502.
34. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St. George-Hyslop P. 2006. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801-808.
35. Miura K, Baba S, Shirasawa H, Ju ST, Cohen AS, Shirahama T. 1992. Intraperitoneal amyloid formation by amyloid enhancing factor rich macrophages in ascitic fluid. Virchows Arch B Cell Pathol Incl Mol Pathol 62:245-250.
36. Monsonego A, Weiner HL. 2003. Immunotherapeutic approaches to Alzheimer's disease. Science 302:834-838.
37. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. 2004. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25:663-674.
38. Nobusawa A, Taniguchi T, Fujioka Y, Inoue H, Shimizu H, Ishikawa Y, Yokoyama M. 2000. Glibenclamide inhibits accumulation of cholesteryl ester in THP-1 human macrophages. J Cardiovasc Pharmacol 36:101-108.
39. Radenovic L, Kartelija G. 2004. Effect of chlorpromazine on human and murine intracellular carboxylesterases. Biochemistry (Moscow) 69:381-386.
40. Romeis B, Böck P. 1989. Mikroskopische Technik. Urban & Fischer Bei Elsevier.
41. Sachse C, Xu C, Wieligmann K, Diekmann S, Grigorieff N, Fandrich M. 2006. Quaternary structure of a mature amyloid fibril from Alzheimer's abeta(1-40) Peptide. J Mol Biol 362:347-354.
42. Schenk D, Hagen M, Seubert P. 2004. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16:599-606.
43. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. 1999. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154:1673-1684.
44. Tagouri YM, Sanders PW, Picken MM, Siegal GP, Kerby JD, Herrera GA. 1996. In vitro AL-amyloid formation by rat and human mesangial cells. Lab Invest 74:290-302.
45. Van der Hilst JC, Simon A, Drenth JP. 2005. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 5:87-98.
46. Wegiel J, Wisniewski HM. 1990. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol 81:116-124.
47. Weltzien RB, Pachter JS. 2000. Visualization of beta-amyloid peptide (Abeta) phagocytosis by human mononuclear phagocytes: dependency on Abeta aggregate size. J Neurosci Res 59:522-527.
48. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters C L, Merlini G, Saraiva MJ, Sipe JD. 2005. Nomenclature Committee of the International Society of Amyloidosis. Amyloid: toward terminology clarification. Amyloid 12:1-4.
49. Williamson MP, Suzuki Y, Bourne NT, Asakura T. 2006. Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13. Biochem J 397:483-490.
50. Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE. 2005. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 25:1071-1080.
51. Yazawa H, Yu ZX, Takeda K, Le Y, Gong W, Ferrans VJ, Oppenheim JJ, Li CC, Wang JM. 2001. Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 15:2454-2462.